

**QUESTIONS AND ANSWERS  
REGARDING JAPANESE PATENT PRACTICE  
TABLE OF CONTENTS**

QUESTIONS AND ANSWERS compiled  
by the International Activities Center of  
the Japan Patent Attorneys Association<sup>1</sup>

**I. APPLICATION**

<b>Proxy</b> .....	<b>P.1</b>
Q1.Representing Competitors	
Q2.Pro Se Application	
<b>Formality</b> .....	<b>P.2</b>
Q3.When Corporate Nationality Certificate Cannot be Notarized	
Q4.Electronic Filing of Drawings	
Q5.Filing in English Language	
Q6.Coloring Design Application	
<b>Specification and Claims</b> .....	<b>P.7</b>
Q7.Missing "Object"	
Q8.Inappropriate "Object"	
Q9."Problems" and "Advantageous Effects"	
Q10.Several "Advantages"	
Q11.Claim Format	
Q12.Dependent Claims	
Q13.Unity of Invention	
<b>Chemical data</b> .....	<b>P.15</b>
Q14.Toxicity Data	
Q15.Physical-Chemical Data	
Q16.Physical data or Test Data of a Compound	
Q17.U.S. Application Lacking Data	
Q18.Paper Examples	
Q19.Prophetic Examples	
<b>Biotechnology</b> .....	<b>P.20</b>
Q20.Deposit of Microorganism or Biotech Material	

---

<sup>1</sup> The members of the International Activities Center on this project are Kenji ASAI, Kanji FUJIYOSHI, Fujihiko KANDA, Shuhei KATAYAMA, Yoshihiko KIDO, Shinichi KIMURA, Hiroshi KOBAYASHI, Tomoya KUROKAWA, Takao MATSUI, Takanori NAKAJIMA, Nobuyuki NISHIKAWA, Takeshi NONAKA, Toshiharu OGAWA, Makoto ONDA, Yoko SAKUMA, Takahisa SATOH, Yasumitsu SUZUKI, Yukihiisa TAMAKUSHI, Yoshikazu TANI, Hitoshi WADA, Masashi YANAGIDA and Tamaki YOSHIDA.

Q21.Submitting of Sequence Listing	
Q22.Patenting Transgenic Animals	
<b>Divisional Application.....</b>	<b>P.23</b>
Q23.When a Divisional Application can be filed	
Q24.Requirements for Divisional Application	
Q24-2.Conversion to Utility Model	
<b>Claiming Priority.....</b>	<b>P.28</b>
Q25.Inventors to be Included	
Q26.Can Omitted Priority be Corrected?	
Q27.Claiming Both U.S. and Japanese Priorities	
Q28.Hypothetical Case and Discussion	
Q29.Hypothetical Case and Discussion, Continued	
<b>Internal Priority.....</b>	<b>P.33</b>
Q30.How Internal Priority is Claimed	
Q31.How Double Patenting is Avoided	
<b>National Phase Entry of PCT Application.....</b>	<b>P.34</b>
Q32.Nationalizing a PCT Application	
<b>Utility Model.....</b>	<b>P.36</b>
Q33.Utility Model System in Japan	
<b>Fees.....</b>	<b>P.39</b>
Q34.How Official Fees are determined for Claims?	
Q35.Attorney's Fees	
<b>Others.....</b>	<b>P.41</b>
Q36.Non-Inventor's Application	
Q37."Time" vs. "Day" of Application	

## **II. PATENTABILITY**

<b>Novelty; Publication.....</b>	<b>P.44</b>
Q38.Defenition of "Publication"	
Q39.Disclosure through the Internet	
Q40.Defenition of "Distributed"	
Q41.Date of "Publication"	
Q42.Distribution of a Paper for Evaluation before Printing	
<b>Novelty; Presentation, Display, Sale.....</b>	<b>P.47</b>
Q43.Oral Presentation	
Q44.Overseas Presentation Before Japanese Nationals	
Q45.Display at an International Trade Show	
Q46.Selling; a Product Made by a Secret Process	
<b>Grace Period.....</b>	<b>P.50</b>

- Q47. Inventor not residing in Japan
- Q48. Prior art within Grace Period
- Q49. Definition of "Presentation in a Printed Publication"
- Q50. Presentation on the Internet
- Q51. Lack of Novelty outside Japan

**Whole Content Approach.....P.54**

- Q52. Date considered; In re Hilmer Doctrine

**Chemical Invention.....P.54**

- Q53. New Compound as to Which Way of Functioning is Unknown
- Q54. Second Purpose of a Known Pharmaceutical
- Q55. Sale of a Chemical Composition in the U.S.
- Q56. Industrial Utility of an Intermediate
- Q57. Rejecting a Later Filed Application
- Q57-2. Experimental Use
- Q58. JPO Policy on Patenting High Temperature Superconductors

**Software Invention.....P.61**

- Q59. Patentability of Software
- Q60. Getting Allowance of Software Related Inventions
- Q61. Case Law Relied Upon in Deciding Patentability

**III. EXAMINATION**

**Submission by a Third Party of Relevant Information on the Prior Art etc.....P.71**

- Q62. When can the information be submitted?
- Q62-2. Who can submit the information?
- Q62-3. What kind of information can be submitted?
- Q62-4. How is the feedback to the provider of the information done?
- Q63. How to inform an applicant of the submission of the information?
- Q64. Is the information submission system effected?
- Q64-2. Are there any disadvantages?

**Expediting Examination.....P.73**

- Q65. "Preferential" Examination vs. "Accelerated" Examination
- Q66. Effect of Expediting
- Q67. Requirements for Accelerated Examination

**Office Action.....P.75**

- Q68. Standard of Obviousness or Lack of Inventive Step

- Q69.Examiner Considered as Skilled in the Art
- Q70.Affidavits to Evidence the Knowledge of a Person Skilled in the Art
- Q71.Declarations to Support Broad Claims
- Q72.After the Maximum Term of Patent
- Q73.Extension of Time for Responding to Office Action

**Amendment.....P.79**

- Q74.Amending Junior Application to Have it Read on Senior Application (Senior application and junior application)
- Q75.Amending Japanese Claims to Parallel Issued Foreign Claims
- Q76.Advantage of Paralleling Issued Foreign Claims
- Q77.Further Narrowing the Paralleled Claims
- Q78.How is the "New Matter" determined?
- Q79.the New rule regarding a prohibited amendment which changes the special technical features of invention
- Q80.Amendments Challenged by Third Parties

**Interview.....P.89**

- Q81.Interview Recommended
- Q82.Recommended Strategy for interview

**IV. INFRINGEMENT**

**Claim Interpretation.....P.90**

- Q83.General Claim Interpretation
- Q84.Emphasis of Advantageous Effect Narrowing Scope of Invention
- Q85.Doctrine of Equivalents
- Q86.Pre-Grant Protection and Post-Grant Protection
- Q87.Doctrine of Claims Differentiation
- Q88.Influence by Reference Numerals in claims

**Infringement.....P.95**

- Q89.Averting an Infringement Action/Compulsory License
- Q90.Remedies for Patent Infringement
- Q91.Proof of Infringement of a Method Claim

**V. GENERAL (OTHERS).....P.97**

- Q92.Cultural Differences Underlying Patent Practice
- Q93.The JPO Database